Your Top 50 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
Madan Jagasia, Miguel‐Angel Perales, Mark A. Schroeder, Haris Ali, Nirav Niranjan Shah, Yi‐Bin Chen and 7 more
- Rank
- 28 of 3,950
- Percentile
- top 0.8%
- Where
- Blood, 2020
- Citations
- 309
From the 2020 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.